A first in man study to evaluate the safety, pharmacokinetics and pharmacodynamics of RP7214, a dihydroorotate dehydrogenase inhibitor in healthy subjects

A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses

(2022) Yucheng Zheng et al.   Viruses-Basel

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes

(2021) Kensuke Kayamori et al.   Blood Advances

Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review

(2021) Hardeep Kaur et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dihydroorotate Dehydrogenase Inhibitors in SARS‐CoV‐2 Infection

(2020) Ana R. Coelho et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

(2019) Jianbiao Zhou et al.   HAEMATOLOGICA

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

(2018) Marco L. Lolli et al.   Recent Patents on Anti-Cancer Drug Discovery

The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia

(2018) David B. Sykes   EXPERT OPINION ON THERAPEUTIC TARGETS

Dihydroorotate dehydrogenase: A drug target for the development of antimalarials

(2017) Anju Singh et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response

(2017) Nam Nam Cheung et al.   JOURNAL OF GENERAL VIROLOGY